Summary
Intravesical Adriamycin instillation was used in 10 patients with transitional cell carcinoma of the bladder as postoperative prophylactic treatment against recurrence.
The protocol for bladder instillation was 20 mg/10 ml of Adriamycin twice weekly for a total of eight doses.
One patient developed recurrence in 3 months and three, in 6 months. The main local side-effects were frequency and dysuria which occurred in four cases. Leukopenia and increased SGOT and SGPT values each occurred in one case. No cases of cardiotoxicity, fibrosis, or atrophy of the bladder mucosa were found. Further studies are necessary to achive the best possible results.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Amin M, Lich R (1974) Lymphocytes and bladder cancer. J Urol 111: 165
Banks MD, Pontes JE, Izbicki RM, Pierce JM (1977) Topical instillation of doxorubicin hydrochloride in the treatment of recurring superficial transitional cell carcinoma of the bladder. J Urol 118: 757
Blum RH, Carter SK (1974) Adriamycin, a new anticancer drug with significant clinical activity. Ann Intern Med 80: 249
Catalona WJ, Chretien PB (1973) Correlation among host immunocompetence and tumor stage, tumor grade and vascular permeation in transitional carcinoma. J Urol 110: 526
Catalona WJ, Tarpley JL, Chretien PB, Castle JR (1974) Lymphocyte stimulation in urologic cancer patients. J Urol 112: 373
Greene LF, Hanash KA, Farrow GM (1973) Benign papilloma or papillary carcinoma of the bladder? J Urol 110: 205
Jacobi GH, Kurth KH (1980) Studies on intravesical action of topically administered G3H-doxorubicin hydrochloride in men: Plasma uptake and tumor penetration. J Urol 124: 34
Jakse G, Hofstädter F, Marberger H (1981) Intracavitary doxorubicin hydrochloride therapy for carcinoma in situ of the bladder. J Urol 125: 185
Koontz WW, Prout GR, Smith W, Frable WJ, Minnis JE (1981) The use of intravesical thio-TEPA in the management of non-invasive carcinoma of the bladder. J Urol 125: 307
Loening S, Narayana A, Yoder L, Slymen D, Weinstein S, Penick G, Culp D (1980) Factors influencing the recurrence rate of bladder cancer. J Urol 123: 29
Lutzeyer W, Rübben H, Dahm H (1982) Prognostic parameters in superficial bladder cancer: An analysis of 315 case. J Urol 127: 250
Melicow MM (1974) Tumors of the bladder: A multifaceted problem. J Urol 112: 467
Mclaughlin AP, Kessler WO, Triman K, Gittes RF (1974) Immunologic competence in patients with urologic cancer. J Urol 111: 233
Mishina T, Oda K, Murata S, Ooe H, Mori Y, Takahashi T (1975) Mitomycin C bladder instillation therapy for bladder tumors. J Urol 114: 217
Mitchell R, Chir M (1971) Intravesical thio-TEPA in the treatment of transitional cell bladder carcinoma. Br J Urol 43: 185
Morales A, Ottenhof P, Emerson L (1981) Treatment of residual, non-infiltrating bladder cancer with Bacillus Calmette-Guérin. J Urol 125: 649
Ozaki Y (1977) Bladder instillation of adriamycin in the treatment of bladder tumors. 1. Clinical results. Jap J Urol 68: 934
Riddle PR, Wallace DM (1971) Intracavitary chemotherapy for multiple non-invasive bladder tumors. Br J Urol 43: 181
Robinson MRG, Shetty MB, Richards B, Bastable J, Glashan RW, Smith PH (1977) Intravesical epodyl in the management of bladder tumors: combined experience of the Yorkshire Urological Cancer Research Group. J Urol 118: 972
Soloway MS (1980) Rationale for intensive intravesical chemotherapy for superficial bladder cancer. J Urol 123: 461
Soloway MS, Murphy WM, DeFuria MD, Crooke S, Finebaum P (1981) The effect of mitomycin C on superficial bladder cancer. J Urol 125: 646
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Huang, CH., Chiang, CP. Bladder instillation of Adriamycin in the treatment of bladder cancer. Cancer Chemother. Pharmacol. 11 (Suppl 1), S91–S93 (1983). https://doi.org/10.1007/BF00256728
Issue Date:
DOI: https://doi.org/10.1007/BF00256728